Bauer, Gerhard

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 321

Human COL7A1 -corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa

Sebastiano, V., Zhen, H. H., Haddad, B., Bashkirova, E., Melo, S. P., Wang, P., Leung, T. L., Siprashvili, Z., Tichy, A., Li, J., et al. (2014) · Science Translational Medicine

Pluripotent Stem Cells ResearchSkin and Cellular Biology Research

Cited by 213

Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs

Abou-El-Enein, M., Römhild, A., Kaiser, D., Beier, C., Bauer, G., Volk, H.-D., & Reinke, P. (2013) · Cytotherapy

Pharmaceutical Economics and PolicyBiomedical Ethics and Regulation

Cited by 86

Putting a price tag on novel autologous cellular therapies

Abou-El-Enein, M., Bauer, G., Medcalf, N., Volk, H.-D., & Reinke, P. (2016) · Cytotherapy

Pharmaceutical Economics and PolicyCAR-T cell therapy research

Cited by 44

Human genome editing in the clinic: new challenges in regulatory benefit-risk assessment

Abou-El-Enein, M., Cathomen, T., Ivics, Z., June, C. H., Renner, M., Schneider, C. K., & Bauer, G. (2017) · Cell Stem Cell

CRISPR and Genetic EngineeringBiomedical Ethics and Regulation

Cited by 31